Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilars Pathway In WHO Draft Guidance Drops Dual-track Approach

Executive Summary

A World Health Organization working group dropped the less rigorous of two approaches for regulating biosimilars from its latest draft guidelines, a positive step, according to generic drug maker Sandoz

You may also be interested in...

WHO To Redraft Biosimilars Guidance, Clarify Data Requirements

Expert committee urges countries to move cautiously in licensing biosimilars, even though some products can require reduced data packages.

Draft WHO Guidance Provides Two Pathways For Biosimilars

Clinical trials would be required for most biosimilars under two approval scenarios that are being developed by the World Health Organization

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts